Thermo Fisher Scientific buys Patheon for $7.2 billion

Thermo Fisher Scientific Inc has acquired Patheon NV, the Netherlands-based global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, for $7.2 billion, which includes the assumption of approximately $ 2 billion of net debt. 

Patheon provides comprehensive, integrated and highly customisable solutions as well as the expertise to help biopharmaceutical companies of all sizes satisfy complex development and manufacturing needs. It is a leader in the high-growth, $40 billion CDMO (contract development and manufacturing organisation) market, which is fuelled by growing customer demand for end-to-end solutions, flexible and scalable capacity, and regulatory expertise. Patheon has an extensive network of state-of-the-art facilities primarily in North America and Europe, and approximately 9,000 professionals worldwide. The company generated 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher’s laboratory products and services segment.